In our case-control series from Peru and Chile we observed an increased frequency of Lrrk2 p.Q1111H in patients (7.9 % ) compared to controls (5.4 % ) although the difference did not reach significance (OR 1.38; p?=?0.10).
In addition, the frequency of Lrrk2 p.Q1111H varied greatly between populations and further screening in a set of pure Amerindian and pure Spanish controls suggested that this variant likely originated in an Amerindian population. Further studies in other Latin American populations are warranted to assess its role as a risk factor for Parkinson¡¯s disease. Screening in Parkinson¡¯s disease patients from under-represented populations will increase our understanding of the role of LRRK2 variants in disease risk worldwide.